Association between estimated pharmacokinetic/pharmacodynamic predictions of efficacy and observed clinical outcomes in obese and nonobese patients with …
M Santibañez, K Bunnell, A Harrington… - Open Forum …, 2019 - academic.oup.com
Background Evidence on pharmacokinetic/pharmacodynamic (PK/PD) alterations and
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
Association Between Estimated Pharmacokinetic/Pharmacodynamic Predictions of Efficacy and Observed Clinical Outcomes in Obese and Nonobese Patients With …
M Santibanez, K Bunnell, A Harrington… - Open Forum Infectious …, 2019 - go.gale.com
Background. Evidence on pharmacokinetic/pharmacodynamic (PK/PD) alterations and
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
[PDF][PDF] Association Between Estimated Pharmacokinetic/Pharmacodynamic Predictions of Efficacy and Observed Clinical Outcomes in Obese and Nonobese Patients …
M Santibañez, K Bunnell, A Harrington… - Open Forum …, 2019 - academic.oup.com
Background Evidence on pharmacokinetic/pharmacodynamic (PK/PD) alterations and
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
Association Between Estimated Pharmacokinetic/Pharmacodynamic Predictions of Efficacy and Observed Clinical Outcomes in Obese and Nonobese Patients With …
M Santibañez, K Bunnell, A Harrington… - Open Forum …, 2019 - europepmc.org
Background Evidence on pharmacokinetic/pharmacodynamic (PK/PD) alterations and
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
[HTML][HTML] Association Between Estimated Pharmacokinetic/Pharmacodynamic Predictions of Efficacy and Observed Clinical Outcomes in Obese and Nonobese …
M Santibañez, K Bunnell, A Harrington… - Open Forum …, 2019 - ncbi.nlm.nih.gov
Background Evidence on pharmacokinetic/pharmacodynamic (PK/PD) alterations and
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
Association Between Estimated Pharmacokinetic/Pharmacodynamic Predictions of Efficacy and Observed Clinical Outcomes in Obese and Nonobese Patients With …
M Santibañez, K Bunnell… - Open forum …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Evidence on pharmacokinetic/pharmacodynamic (PK/PD) alterations and
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
[PDF][PDF] Association Between Estimated Pharmacokinetic/Pharmacodynamic Predictions of Efficacy and Observed Clinical Outcomes in Obese and Nonobese Patients …
M Santibañez, K Bunnell, A Harrington, S Bleasdale… - 2019 - pdfs.semanticscholar.org
Background. Evidence on pharmacokinetic/pharmacodynamic (PK/PD) alterations and
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
Association Between Estimated Pharmacokinetic/Pharmacodynamic Predictions of Efficacy and Observed Clinical Outcomes in Obese and Nonobese Patients With …
M Santibañez, K Bunnell, A Harrington… - Open Forum …, 2019 - search.ebscohost.com
Background Evidence on pharmacokinetic/pharmacodynamic (PK/PD) alterations and
clinical outcomes in obese patients with serious infections remains limited. This study aimed …
clinical outcomes in obese patients with serious infections remains limited. This study aimed …